Recent Price Movement and Market Context
On 9 March 2026, Hikal Ltd’s stock touched an intraday low of Rs.172.8, representing a 4.58% drop from the previous close. The stock underperformed its sector by 2.06% on the day, continuing to trade below all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning underscores the prevailing bearish sentiment surrounding the stock.
The broader market environment has also been challenging. The Sensex opened sharply lower by 1,862.15 points and was trading at 76,935.63, down 2.51% on the day. The index has experienced a three-week consecutive decline, losing 7.1% over this period. While the Sensex remains above its 200-day moving average, it is currently below its 50-day moving average, signalling short-term weakness. Additionally, the INDIA VIX index hit a new 52-week high, indicating elevated market volatility.
Long-Term Performance and Valuation Metrics
Over the past year, Hikal Ltd’s stock has delivered a negative return of 53.66%, significantly underperforming the Sensex, which gained 3.44% during the same timeframe. The stock’s 52-week high was Rs.456.6, highlighting the extent of the decline from its peak levels.
From a valuation perspective, the company’s enterprise value to capital employed ratio stands at a modest 1.6, suggesting an attractive valuation relative to its capital base. However, this valuation is tempered by the company’s financial performance and profitability metrics.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
Financial Performance and Profitability Concerns
Hikal Ltd’s financial metrics reveal several areas of concern. The company has experienced a compound annual growth rate (CAGR) decline of 16.94% in operating profits over the last five years, indicating weakening earnings capacity. The return on equity (ROE) averaged 8.00%, reflecting modest profitability relative to shareholders’ funds.
Return on capital employed (ROCE) for the half-year ended December 2025 was notably low at 4.44%, with a recent figure of 4.1% also reported. These figures suggest limited efficiency in generating returns from the company’s capital base.
Debt servicing ability is another area of concern, with a high debt to EBITDA ratio of 2.51 times. This elevated leverage ratio points to increased financial risk and potential constraints on the company’s ability to manage its obligations comfortably.
Recent Earnings and Profitability Trends
The company reported flat results in the December 2025 quarter, with profits declining by 66.4% over the past year. This sharp contraction in profitability has contributed to the stock’s underperformance relative to the BSE500 index over the last three years, one year, and three months.
Despite these challenges, the stock is trading at a discount compared to its peers’ average historical valuations, which may reflect market recognition of the company’s current difficulties.
Why settle for Hikal Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Shareholding and Sectoral Positioning
The majority shareholding in Hikal Ltd remains with the promoters, maintaining a stable ownership structure. The company operates within the Pharmaceuticals & Biotechnology sector, which has experienced mixed performance amid broader market volatility.
Hikal’s Mojo Score currently stands at 23.0, with a Mojo Grade of Strong Sell as of 14 November 2025, an upgrade from the previous Sell rating. The market capitalisation grade is rated at 3, reflecting the company’s mid-tier size within the sector.
Summary of Key Metrics
To summarise, Hikal Ltd’s stock has reached a new 52-week low of Rs.172.8 after a sustained period of decline. The stock’s performance has been impacted by subdued profitability, high leverage, and underwhelming returns on capital. While the valuation appears attractive relative to capital employed, the company’s financial indicators highlight ongoing challenges in earnings growth and debt management.
These factors have contributed to the stock’s underperformance relative to both the Sensex and its sector peers over multiple time horizons.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
